Table 1 Baseline characteristics of patients
SZC group (n = 60) | SPS group (n = 60) | P | |
|---|---|---|---|
Age (years) | 47.4 ± 10.4 | 51.6 ± 13.0 | 0.083 |
Sex | |||
Male | 33 (55%) | 31 (51.6%) | 0.841 |
Female | 27 (45%) | 29 (48.3%) | |
BMI (kg/m2) | 27 ± 4.5 | 27.8 ± 5.9 | 0.449 |
Duration of HD (years) | 7 ± 4.6 | 6.6 ± 6.1 | 0.412 |
Cause of ESRD | |||
Hypertension | 21 (35%) | 27 (45%) | |
DM | 12 (20%) | 15 (25%) | |
Chronic pyelonephritis | 6 (10%) | 3 (5%) | |
Glomerulonephritis (GN) | 8 (13.3%) | 5 (8.3%) | |
ADPCKD | 6 (10%) | 4 (6.6%) | |
Others | 7 (11.6%) | 6 (10%) | |
Potassium raising medications | |||
ACEIs/ARBs use | 5 (8.3%) | 5 (8.3%) | 1.000 |
MRAs use | 1 (1.6%) | 1 (1.6%) | 1.000 |
Vascular access | |||
AVF | 48 (80%) | 54 (90%) | 0.102 |
Catheter | 12 (20%) | 6 (10%) | |
HD prescription | |||
Blood flow rate (ml/min) (QB) | 318.2 ± 41.0 | 307.2 ± 34.1 | 0.146 |
Dialysate flow (ml/hr) (QD) | 594.4 ± 103.5 | 577.2 ± 94.8 | 0.391 |
UF volume (L/session) | 3.7 (2.5 − 4.7) | 3.25 (3 − 4) | 0.147 |
Presence of residual UOP | |||
Yes | 35 (58.3%) | 33 (55%) | 0.732 |
No | 25 (41.7%) | 27 (45%) | |
Total cholesterol (mg/dl) | 179.4 ± 25.8 | 182.2 ± 36.0 | 0.656 |
Serum triglycerides (mg/dl) | 131 (107–178) | 133.5 (115–150) | 0.603 |
Hemoglobin (g/dl) | 9.6 ± 1.8 | 9.6 ± 1.7 | 0.857 |
Albumin (g/dl) | 3.85 ± 0.3 | 3.76 ± 0.4 | 0.218 |
Serum electrolytes | |||
Calcium (mg/dl) | 8.9 ± 1.1 | 9.28 ± 0.9 | 0.078 |
Phosphorus (mg/dl) | 5.8 (4.9–7) | 6 (5.3–6.6) | 0.779 |
Sodium (mEq/L) | 136.1 ± 15.8 | 136.1 ± 3.8 | 0.993 |
Potassium (mEq/L) | 5.6 ± 0.2 | 5.6 ± 0.3 | 0.892 |
Serum PTH (pg/ml) | 301 (132.6–494) | 456 (179–822.5) | 0.180 |
CRP (mg/l) | 5.5 (4–13) | 4.9 (3.2–9.1) | 0.273 |
Kt/V | 1.42 ± 0.3 | 1.40 ± 0.2 | 0.690 |
URR | 69.7 ± 9.6 | 69.5 ± 8.6 | 0.926 |